CŌRE Diagnostics partners with Digistain(R) to revolutionize breast cancer care with new risk profiling technology

CŌRE Diagnostics, a clinical laboratory focused on next-generation diagnostics for disease stratification and therapy selection, has partnered with Digistain.

The company said the partnership aims to bring the UK's first Breast Cancer Risk Profiling Technology, Digistain, to India, Nepal, Bhutan and Bangladesh. 

What is Digistain?

Digistain is a revolutionary digital solution for cancer grading and prognosis, approved by the UK’s Medicines & Healthcare products Regulatory Agency (MHRA).

It offers a rapid, affordable, and AI-enabled solution to predict the likelihood of post-surgery breast cancer recurrence. This technology is designed to prevent breast cancer patients from undergoing unnecessary chemotherapy.

Developed with input from over 1,500 oncologists

Digistain was developed with input from over 1,500 oncologists and has been successfully trialled at prominent cancer centres, such as Nottingham University NHS Trust, the National Institute of Healthcare Research (NIHR), and Cancer Research UK.

The introduction of Digistain in India and its neighbouring states through this partnership is expected to revolutionise the healthcare industry’s approach to breast cancer treatment, the release notes.

 With its AI-enabled technology, Digistain has the potential to enhance diagnostic accuracy, reduce treatment costs, and ultimately save lives.

The collaboration aligns with India's broader healthcare objectives of leveraging innovative solutions to address pressing healthcare challenges and improve patient care nationwide.

Who is Dr. Hemmel Amrania?

Dr. Hemmel Amrania, PhD, the Chief Executive Officer of Digistain, has been instrumental in developing this technology.

With a clinical science background from Imperial College and Université Paris XI, his innovative research led to a novel diagnostic method that dramatically improves patient outcomes in early-stage cancer, garnering the prestigious President’s Award for Outstanding Research. Dr Amrania brings a wealth of knowledge and expertise to this partnership.

CŌRE Diagnostics leadership

Dinesh Chauhan, the CEO of CŌRE Diagnostics, brings over 25 years of rich experience in various verticals across the Diagnostics Industry and has witnessed the industry's transition.

He has a proven track record of bringing many innovative diagnostic tests to India and was instrumental in creating a market for the new tests. His leadership and strategic vision will be crucial in bringing Digistain to India.

“This partnership represents a significant step forward in the fight against breast cancer by providing a faster, more accurate, and cost-effective approach to cancer prognosis and treatment. CŌRE Diagnostics and Digistain® are committed to improving patient outcomes and transforming the landscape of healthcare”, said Chauhan